U.S. Markets close in 1 hr 22 mins
  • S&P 500

    4,479.79
    +8.42 (+0.19%)
     
  • Dow 30

    35,212.74
    -82.02 (-0.23%)
     
  • Nasdaq

    14,995.80
    +98.46 (+0.66%)
     
  • Russell 2000

    2,268.39
    +2.74 (+0.12%)
     
  • Gold

    1,767.20
    -1.10 (-0.06%)
     
  • EUR/USD

    1.1616
    +0.0015 (+0.1278%)
     
  • 10-Yr Bond

    1.5810
    +0.0620 (+4.08%)
     
  • Vix

    16.47
    +0.17 (+1.04%)
     
  • GBP/USD

    1.3734
    +0.0057 (+0.4148%)
     
  • USD/JPY

    114.2350
    +0.5580 (+0.4909%)
     
  • BTC-USD

    62,009.52
    +1,059.59 (+1.74%)
     
  • CMC Crypto 200

    1,443.81
    -7.83 (-0.54%)
     
  • FTSE 100

    7,203.83
    -30.20 (-0.42%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences:

  • Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020 where management will participate in 1x1 meetings. A fireside chat held with Seres management will be made available on the News and Events section of the Company’s website on November 23, 2020.

  • 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 2, 2020. Management will participate in 1x1 meetings.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005223/en/

Contacts

PR Contact
Lisa Raffensperger
lisa@tenbridgecommunications.com

IR Contact
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com